Quantum BioPharma's Market Manipulation Allegations Featured in CTV W5 Investigative Report

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that CTV News' investigative program W5 has aired Part 2 of its three-part series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The segment, reported by award-winning journalist Jon Woodward, highlights the company's claims of widespread market manipulation and its impact on Quantum BioPharma's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment.

CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged activity, noting that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms. The company maintains that this alleged market manipulation has significantly affected its stock price and ability to raise capital for developing its lead compound, Lucid-MS, which is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.

Quantum BioPharma's lawsuit against CIBC and RBC represents a substantial legal challenge in the financial sector, with the company seeking $700 million in damages. The CTV W5 coverage brings increased public attention to these allegations at a time when regulatory scrutiny of market practices is intensifying. The investigative segment provides a platform for the company to present its evidence and arguments to a broader audience beyond the financial and legal communities.

The company's focus on developing treatments for neurodegenerative disorders gives these allegations particular significance, as any disruption to funding or market confidence could delay potential medical advancements. Quantum BioPharma's portfolio includes innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with Lucid-MS representing its most advanced candidate. The company also maintains strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Investors seeking additional information about Quantum BioPharma can access the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM. The full press release containing details about the CTV W5 coverage is available at https://ibn.fm/t3Tex. This media attention comes as the company continues to advance its clinical development programs while navigating the legal challenges outlined in its lawsuit against the financial institutions.